



**Study Published in European Society for Medical Oncology (ESMO) Open  
Highlights Preliminary Clinical Activity of Aminex Therapeutics' Dual  
Agent Immunotherapy Treatment Approach**

- *Results from Phase 1 trial of AMXT 1501 plus DFMO (difluoromethylornithine)*
  - *Total of 56 patients with advanced solid tumors were treated*
- *The treatment was safe and well-tolerated with early encouraging signals of clinical benefit*

**September 10, 2025, Seattle, WA** – [Aminex Therapeutics, Inc.](#), a private clinical-stage biotechnology company focused on advancing a novel cancer immunotherapy, today announced the publication of clinical trial results of its investigational dual agent immunotherapy treatment in the peer-reviewed journal [ESMO Open](#).

The publication details results of a multicenter Phase 1 dose-escalation study to evaluate the safety and preliminary efficacy of oral AMXT 1501 in combination with oral DFMO in patients with advanced solid tumors. Patients with unresectable, locally advanced, or metastatic solid tumors for which no standard therapy was recognized were eligible. A total of 56 patients were treated, with a median number of 10 prior treatments.

Key findings include:

- Overall, treatment was safe and well-tolerated. The most common treatment-emergent adverse events (TEAEs) were diarrhea, nausea, and vomiting. There were no grade 4 or 5 TEAEs and no deaths due to TEAEs.
- Encouraging antitumor activity was observed, with 2 patients with confirmed responses, one patient with advanced HR+ve, HER2-ve breast cancer and the second patient with advanced diffuse midline glioma. In addition, 16 patients with

stable disease in various end stage solid tumor types had an overall response rate of 6% and a clinical benefit rate of 49%.

“This study underscores the tolerability and preliminary activity of our treatment approach, including notable clinical effects in patients who had failed 10 or more prior treatments,” said Mark Burns, PhD, President and Chief Science Officer. “We look forward to advancing this treatment regimen in two separate clinical studies, one for adult cancer patients and one for childhood cancers later this year.”

This latest publication adds to the growing body of research supporting Aminex’ immunotherapy approach. In January 2025, a peer-reviewed publication in [International Journal of Cancer](#) detailed the positive impacts of treatment in acute pediatric leukemia. The preclinical study, sponsored by the Children’s Cancer Institute in Sydney, Australia, showed treatment synergistically inhibited the growth of acute leukemia cell lines. A peer-reviewed report in [Molecular Oncology](#) confirmed the synergistic effects of AMXT 1501 and DFMO in disrupting the polyamine pathway in neuroblastoma.

The complete manuscript in ESMO Open can be accessed [here](#).

### **About Aminex Therapeutics**

Aminex Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of a novel small molecule combination immunotherapy for the treatment of cancer. Aminex has advanced AMXT 1501 through target discovery, patenting, pre-clinical research and into clinical development. For more information, please visit [www.aminextx.com](http://www.aminextx.com).

# # #

### **Media Contact:**

Julie Rathbun  
Rathbun Communications  
[Julie@rathbuncomm.com](mailto:Julie@rathbuncomm.com)  
206-769-9219